PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
Rhea-AI Summary
PolyPid (Nasdaq: PYPD) will report first quarter 2026 financial results and operational highlights before U.S. markets open on Wednesday, May 13, 2026.
The company will host a conference call and webcast at 8:30 AM Eastern Time. Registration is recommended at least 5 minutes before the call; a webcast option is available for listeners.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – PYPD
On the day this news was published, PYPD declined 0.44%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 28 | Earnings date set | Neutral | -1.7% | Announced Q4 2025 earnings call date and reiterated D-PLEX100 NDA timing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
For prior earnings date announcements, the stock showed a small negative reaction of -1.67% following the previous event.
Over recent months, PolyPid has combined clinical and regulatory milestones with routine corporate communications. For earnings-related news, the prior event on January 28, 2026 set a date to report Q4 2025 results and reiterated expectations to submit a D-PLEX100 NDA in early 2026. That announcement was followed by a modest -1.67% move, indicating historically limited share-price impact from scheduling earnings calls compared with more substantive clinical or regulatory updates.
Historical Comparison
In the past, PYPD’s earnings date announcement on Jan 28, 2026 led to an average move of -1.67%. Today’s first quarter 2026 earnings date notice appears similar in nature, suggesting historically muted price impact for this type of news.
The company continues its pattern of pre-announcing quarterly financial results and hosting conference calls to update investors on operations alongside its D-PLEX100 regulatory progress.
Regulatory & Risk Context
AI-generated analysis. How Rhea-AI works. Not financial advice.
PETACH TIKVA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its first quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 13, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, May 13, 2026 |
| Time: | 8:30 AM Eastern Time |
| Conference Call: | https://register-conf.media-server.com/register/BI510ef0c33b114b5b87c2bd9d3c34e882 |
| Webcast: | https://edge.media-server.com/mmc/p/w3mvdb4o |
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.
Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com
Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
polypid@arxhq.com
